Hypofractionated Radiation Acceptable for Localized Prostate Cancer
By MedImaging International staff writers Posted on 05 Nov 2018 |
A new study supports the use of shortened courses of radiation therapy (RT) for early-stage prostate cancer (PC).
Researchers at the University of Ottawa (Canada), Cedars-Sinai Medical Center (Los Angeles, CA, USA), Vanderbilt University Medical Center (VUMC; Nashville, TN, USA), and other institutions participating in a new task force convened by the American Society for Radiation Oncology (ASTRO) conducted a systematic literature review to address key questions and develop an evidence-based guideline for dose-fractionation RT for early-stage PC.
Among the issues discussed were technical aspects, including normal tissue dose constraints, treatment volumes, and use of image guided RT (IMRT) and intensity modulated RT (IMRT). Based on high-quality evidence, a strong consensus was reached to offer moderate hypofractionation across risk groups to patients choosing external beam RT (EBRT), and recommended ultrahypofractionated RT for low- and intermediate-risk PC. For high-risk patients, the routine use of ultrahypofractionated EBRT was not recommended. The study was published on October 11, 2018, in Practical Radiation Oncology.
“These recommendations are intended to provide guidance on moderate hypofractionation and ultrahypofractionation for localized prostate cancer. Men who opt to receive hypofractionated radiation therapy will be able to receive a shorter course of treatment,” concluded lead author Scott Morgan, MD, of the University of Ottawa, and colleagues. “The limits in the current evidentiary base, especially for ultrahypofractionation, highlight the imperative to support large-scale randomized clinical trials and underscore the importance of shared decision making between clinicians and patients.”
RT fractionation is defined as a fraction size of 180 to 200 cGy. Hypofractionation is subdivided into moderate hypofractionation (240-340 cGy) and ultrahypofractionation (a fraction size higher 500 cGy). These pragmatic definitions reflect two distinct approaches to hypofractionation that have emerged in clinical practice. The fraction size gap created (i.e., the gap from 340 cGy and 500 cGy) represents a little-studied range.
Related Links:
University of Ottawa
Cedars-Sinai Medical Center
Vanderbilt University Medical Center
Researchers at the University of Ottawa (Canada), Cedars-Sinai Medical Center (Los Angeles, CA, USA), Vanderbilt University Medical Center (VUMC; Nashville, TN, USA), and other institutions participating in a new task force convened by the American Society for Radiation Oncology (ASTRO) conducted a systematic literature review to address key questions and develop an evidence-based guideline for dose-fractionation RT for early-stage PC.
Among the issues discussed were technical aspects, including normal tissue dose constraints, treatment volumes, and use of image guided RT (IMRT) and intensity modulated RT (IMRT). Based on high-quality evidence, a strong consensus was reached to offer moderate hypofractionation across risk groups to patients choosing external beam RT (EBRT), and recommended ultrahypofractionated RT for low- and intermediate-risk PC. For high-risk patients, the routine use of ultrahypofractionated EBRT was not recommended. The study was published on October 11, 2018, in Practical Radiation Oncology.
“These recommendations are intended to provide guidance on moderate hypofractionation and ultrahypofractionation for localized prostate cancer. Men who opt to receive hypofractionated radiation therapy will be able to receive a shorter course of treatment,” concluded lead author Scott Morgan, MD, of the University of Ottawa, and colleagues. “The limits in the current evidentiary base, especially for ultrahypofractionation, highlight the imperative to support large-scale randomized clinical trials and underscore the importance of shared decision making between clinicians and patients.”
RT fractionation is defined as a fraction size of 180 to 200 cGy. Hypofractionation is subdivided into moderate hypofractionation (240-340 cGy) and ultrahypofractionation (a fraction size higher 500 cGy). These pragmatic definitions reflect two distinct approaches to hypofractionation that have emerged in clinical practice. The fraction size gap created (i.e., the gap from 340 cGy and 500 cGy) represents a little-studied range.
Related Links:
University of Ottawa
Cedars-Sinai Medical Center
Vanderbilt University Medical Center
Latest Nuclear Medicine News
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure
- New PET Radiotracer Aids Early, Noninvasive Detection of Inflammatory Bowel Disease
- Combining Amino Acid PET and MRI Imaging to Help Treat Aggressive Brain Tumors